ERC-RMB Research News

2014-2015 Research Highlights

September 6, 2015

The ERC-RMB team continued to gain experience and deepen its knowledge base, leading to the development of various Mg-based alloys especially with different processing routes and conditions. Center scientists continued to progress on innovative non-biomedical technologies that are being developed or discovered while they investigated fundamental scientific issues in areas such as alloy development, coatings technology, corrosion control, sensor development and miniaturization, and so forth. Selected key accomplishments include listing of research-related activities, publications, patents, key meetings, sponsorships and ERC technology transfer. 

ERC-RMB Accelerates Arteriovenous Fistula Stent Development and Commercialization

June 3, 2015

A biodegradable drug-eluting stent that incorporated several ERC proprietary technologies was successfully tested in a pig model in Y7. In the one-month in vivo experiment, the biodegradable stent demonstrated the ability to dilate the arteriovenous fistula (AVF) and increase the blood flow in the AVF with no observed negative response. The technologies incorporated in the AVF stents include an anti-proliferation polymer coating developed by the Dr. Wagner group, design and simulation by Dr. Yin, novel Mg alloy by Drs. Kumta and Xu, the pig AVF model by Dr. Roy-Chaudhury, and manufacturing technology by Drs. Shanov and Yin. During the in vivo testing, H2 sensors were used to measure the degradation of the stent by Dr. Heineman’s group. The ERC has established IP on most of these technologies. 

Bioresorbable Implants Activity with nanoMAG

June 4, 2015

Engagement of ERC-RMB with small businesse company nanoMAG , an Industrial Advisory Boar Members of the ERC led to nanoMag receiving a SECO award, as well as increased interest from potential licensors of their proprietary technology. The ERC continues to work closely with nanoMag to design and conduct studies under the SECO award that would address questions related to translational potential for nanoMag posed by their potential investors. The ERC team’s synergistic relationship on the recent progress in examining histology of bioresorbable implants with nanoMAG, was featured in Dec 2014 Chemical Engineering Progress and at the NSF. 

 

NC A&T TV coverage of Wake collaboration - NASA space study on Knee and Hip joint

January 15, 2015

UNC TV- PBS did a segment in Dec, 2014 about the NASA work going at Wake Forest University lead by Dr. Willey, and NCAT imaging collaboration lead by Dr. Collins of ERC/CAMSS.   This related to study on Knee and hip joints at space.

The NASA study will ramp up in the coming next months between the two technical leaders

http://video.unctv.org/video/2365388403/

(Please view the video by opening the link and then right clicking and choosing "refresh")

Firstly, Dr Willey/ Wake Forest discusses his mice on the International Space station project (19:50 th minute)

ERC participation and capabilities (starts at 24:00 but especially 25:15 ff).

ERC-RMB Accelerates Arteriovenous Fistula Stent Development and Commercialization with Support from the University of Cincinnati

May 2, 2014

A product discovery team from a major medical device company visited the University of Cincinnati (UC). The team met with ERC leaders and PIs including Dr. Mark Schulz, Dr. Prabir Roy-Chaudhury, Dr. Vesselin Shanov and Dr. Zhangzhang Yin, and toured Dialysis Vascular Access Research Lab, NanoWorld Labs and Dialysis Clinic. The meeting was productive and both sides expressed interest in further collaboration. Dr. Dorothy Air, associate senior vice president for entrepreneurial affairs and technology commercialization, attended the meeting and conveyed that the University values technology commercialization and collaboration with industry.  A similar meeting will be held with other potential industrial collaborators. These activities are an outcome of maturation of ERC biodegradable implant technology and ERC’s active efforts of seeking industry participation in research and commercialization. The Arteriovenous fistula (AVF) stent project is currently funded by the UC commercialization Accelerator, a  program formed at the University of Cincinnati (UC) campus to create startup companies—ultimately leading to job creation—and to  position promising early-stage research by UC faculty for commercialization.

More Research News: